Chinese innovative drugs developer Allist Pharmaceuticals announced on Thursday that it has raised RMB1.18 billion (US$170.75 million) in a new funding round led by healthcare-focused private equity firm Shiyu Capital. The new round also drew participation from a group of investors, among which were Chinese private equity firm Loyal Valley Capital, life sciences-specialized BioVenture, Neovision […] Chinese Innovative Drugs Developer Nets $170M Eyeing High Blood Pressure Treatment comes originally from China Money Network. All Rights Reserved.